Moderna (MRNA) shares rose over 7% in Monday's premarket after the company, as per Bloomberg, said it has been working on early-stage vaccines targeting hantaviruses.
The vaccine maker said its research is still at an early stage and had begun before recent infections were reported aboard the Dutch-flagged Hondius, according to Bloomberg. The work is being carried out with the U.S. Army Medical Research Institute of Infectious Diseases and the Korea University College of Medicine, the report said.
Moderna said its broader strategy includes preparing for emerging health threats using its mRNA platform, which can be adapted more quickly than conventional vaccine technologies, the report added.
Price: 58.43, Change: +4.08, Percent Change: +7.51
